Literature DB >> 19324150

Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison.

Hadhami Hamdi1, Akira Furuta, Valérie Bellamy, Alain Bel, Etienne Puymirat, Séverine Peyrard, Onnik Agbulut, Philippe Menasché.   

Abstract

BACKGROUND: Multiple needle-based injections of cells in the myocardium are associated with a low engraftment rate, which may limit the benefits of the procedure. This study used skeletal myoblasts to perform a head-to-head comparison of conventional injections with epicardial deposition of scaffold-embedded cells.
METHODS: Four weeks after ligation-induced myocardial infarction, 40 rats were randomly allocated to receive intramyocardial injections of 5 million human skeletal myoblasts or control medium or to have the infarcted area covered with either a bilayer myoblast cell sheet prepared from a fibrin-coated culture plate or a myoblast-seeded collagen sponge (Gelfoam; Pharmacia & Upjohn, Kalamazoo, MI). End points, assessed after 1 month, included left ventricular function blindly measured by echocardiography, quantification of cell engraftment by quantitative real-time polymerase chain reaction and immunostaining, histologic assessment of fibrosis and angiogenesis, and tissue levels of host-specific angiogenic and antifibrotic cytokines.
RESULTS: Compared with control medium- or myoblast-injected hearts, those receiving the two cell constructs demonstrated the highest recoveries of left ventricular function (p = 0.004 versus controls). Both myoblast cell sheets and myoblast-seeded Gelfoam sponges also resulted in significantly greater angiogenesis compared with controls. The Gelfoam group was associated with the best outcome with regard to the number of engrafted donor cells (p = 0.03 versus myoblasts) and the reduction of fibrosis (p = 0.02 and p = 0.04 versus the control and myoblast groups, respectively).
CONCLUSIONS: Compared with injections, delivery of myoblasts in a construct overlaying the infarcted area is associated with better graft functionality, possibly because of maintenance of improved cell patterning. The cell-seeded Gelfoam construct was found to feature a user-friendly, reproducible, and atraumatic technique.

Entities:  

Mesh:

Year:  2009        PMID: 19324150     DOI: 10.1016/j.athoracsur.2008.12.074

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  33 in total

1.  Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model.

Authors:  D Ladage; I C Turnbull; K Ishikawa; Y Takewa; K Rapti; C Morel; I Karakikes; L Hadri; J Müller-Ehmsen; K D Costa; R J Hajjar; Y Kawase
Journal:  Gene Ther       Date:  2011-04-21       Impact factor: 5.250

2.  In vitro culture of epicardial cells from adult zebrafish heart on a fibrin matrix.

Authors:  Jieun Kim; Nicole Rubin; Ying Huang; Tai-Lan Tuan; Ching-Ling Lien
Journal:  Nat Protoc       Date:  2012-01-19       Impact factor: 13.491

Review 3.  Embryonic stem cells for severe heart failure: why and how?

Authors:  Philippe Menasché
Journal:  J Cardiovasc Transl Res       Date:  2012-03-13       Impact factor: 4.132

4.  Current and future status of stem cell therapy in heart failure.

Authors:  David A D'Alessandro; Robert E Michler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-12

5.  Fibrin acts as biomimetic niche inducing both differentiation and stem cell marker expression of early human endothelial progenitor cells.

Authors:  M C Barsotti; A Magera; C Armani; F Chiellini; F Felice; D Dinucci; A M Piras; A Minnocci; R Solaro; G Soldani; A Balbarini; R Di Stefano
Journal:  Cell Prolif       Date:  2011-02       Impact factor: 6.831

6.  Engineered fetal cardiac graft preserves its cardiomyocyte proliferation within postinfarcted myocardium and sustains cardiac function.

Authors:  Kazuro L Fujimoto; Kelly C Clause; Li J Liu; Joseph P Tinney; Shivam Verma; William R Wagner; Bradley B Keller; Kimimasa Tobita
Journal:  Tissue Eng Part A       Date:  2011-01-16       Impact factor: 3.845

7.  Injectable shear-thinning hydrogels used to deliver endothelial progenitor cells, enhance cell engraftment, and improve ischemic myocardium.

Authors:  Ann C Gaffey; Minna H Chen; Chantel M Venkataraman; Alen Trubelja; Christopher B Rodell; Patrick V Dinh; George Hung; John W MacArthur; Renganaden V Soopan; Jason A Burdick; Pavan Atluri
Journal:  J Thorac Cardiovasc Surg       Date:  2015-07-17       Impact factor: 5.209

8.  Preconditioning of skeletal myoblast-based engineered tissue constructs enables functional coupling to myocardium in vivo.

Authors:  Philipp Treskes; Klaus Neef; Sureshkumar Perumal Srinivasan; Marcel Halbach; Christof Stamm; Douglas Cowan; Maximilian Scherner; Navid Madershahian; Thorsten Wittwer; Jürgen Hescheler; Thorsten Wahlers; Yeong-Hoon Choi
Journal:  J Thorac Cardiovasc Surg       Date:  2014-09-18       Impact factor: 5.209

9.  Bone Marrow Very Small Embryonic-Like Stem Cells: New Generation of Autologous Cell Therapy Soon Ready for Prime Time?

Authors:  David M Smadja
Journal:  Stem Cell Rev Rep       Date:  2017-04       Impact factor: 5.739

10.  Effects of scaffold material used in cardiovascular surgery on mesenchymal stem cells and cardiac progenitor cells.

Authors:  Chani Hodonsky; Lakshmi Mundada; Shuyun Wang; Russell Witt; Gary Raff; Sunjay Kaushal; Ming-Sing Si
Journal:  Ann Thorac Surg       Date:  2014-12-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.